KR970704691A - 류코트리엔 길항제로서의 퀴놀린 유도체(Quinoline derivatives as leukotriene antagonists) - Google Patents
류코트리엔 길항제로서의 퀴놀린 유도체(Quinoline derivatives as leukotriene antagonists) Download PDFInfo
- Publication number
- KR970704691A KR970704691A KR1019970700296A KR19970700296A KR970704691A KR 970704691 A KR970704691 A KR 970704691A KR 1019970700296 A KR1019970700296 A KR 1019970700296A KR 19970700296 A KR19970700296 A KR 19970700296A KR 970704691 A KR970704691 A KR 970704691A
- Authority
- KR
- South Korea
- Prior art keywords
- hydrogen
- acid
- compound
- formula
- salts
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 239000003199 leukotriene receptor blocking agent Substances 0.000 title abstract 3
- 229940027991 antiseptic and disinfectant quinoline derivative Drugs 0.000 title 1
- 125000002943 quinolinyl group Chemical class N1=C(C=CC2=CC=CC=C12)* 0.000 title 1
- 229910052739 hydrogen Inorganic materials 0.000 claims abstract 16
- 239000001257 hydrogen Substances 0.000 claims abstract 16
- 150000001875 compounds Chemical class 0.000 claims abstract 14
- 150000002431 hydrogen Chemical class 0.000 claims abstract 10
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims abstract 6
- 229910052717 sulfur Inorganic materials 0.000 claims abstract 6
- 229920006395 saturated elastomer Polymers 0.000 claims abstract 5
- 229910052736 halogen Inorganic materials 0.000 claims abstract 4
- 150000002367 halogens Chemical class 0.000 claims abstract 4
- 229910052760 oxygen Inorganic materials 0.000 claims abstract 3
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims abstract 3
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims abstract 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims abstract 2
- 150000001768 cations Chemical class 0.000 claims abstract 2
- 125000004093 cyano group Chemical group *C#N 0.000 claims abstract 2
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims abstract 2
- 125000001183 hydrocarbyl group Chemical group 0.000 claims abstract 2
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims abstract 2
- 125000001424 substituent group Chemical group 0.000 claims abstract 2
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims abstract 2
- -1 alkali metal cation Chemical class 0.000 claims 7
- 150000003839 salts Chemical class 0.000 claims 5
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims 3
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 claims 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 claims 2
- 206010002383 Angina Pectoris Diseases 0.000 claims 2
- 206010003210 Arteriosclerosis Diseases 0.000 claims 2
- 201000004624 Dermatitis Diseases 0.000 claims 2
- 201000005569 Gout Diseases 0.000 claims 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims 2
- 206010020751 Hypersensitivity Diseases 0.000 claims 2
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 claims 2
- 208000019695 Migraine disease Diseases 0.000 claims 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 claims 2
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 claims 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 claims 2
- 208000027418 Wounds and injury Diseases 0.000 claims 2
- 208000011341 adult acute respiratory distress syndrome Diseases 0.000 claims 2
- 201000000028 adult respiratory distress syndrome Diseases 0.000 claims 2
- 229910052783 alkali metal Inorganic materials 0.000 claims 2
- 230000007815 allergy Effects 0.000 claims 2
- 150000001412 amines Chemical class 0.000 claims 2
- 208000011775 arteriosclerosis disease Diseases 0.000 claims 2
- 208000006673 asthma Diseases 0.000 claims 2
- 150000001728 carbonyl compounds Chemical class 0.000 claims 2
- 238000006243 chemical reaction Methods 0.000 claims 2
- 125000001309 chloro group Chemical group Cl* 0.000 claims 2
- 230000006378 damage Effects 0.000 claims 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 claims 2
- 125000001153 fluoro group Chemical group F* 0.000 claims 2
- 238000005984 hydrogenation reaction Methods 0.000 claims 2
- 230000004968 inflammatory condition Effects 0.000 claims 2
- 208000014674 injury Diseases 0.000 claims 2
- 230000000302 ischemic effect Effects 0.000 claims 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 206010027599 migraine Diseases 0.000 claims 2
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 claims 2
- 230000002062 proliferating effect Effects 0.000 claims 2
- 208000002815 pulmonary hypertension Diseases 0.000 claims 2
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 2
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 claims 2
- SMBSMAXNHQVHLG-OZXNKBQZSA-N (2s)-2-[2-[[3-[(e)-2-(7-chloroquinolin-2-yl)ethenyl]anilino]methyl]phenoxy]hexanoic acid Chemical compound CCCC[C@@H](C(O)=O)OC1=CC=CC=C1CNC1=CC=CC(\C=C\C=2N=C3C=C(Cl)C=CC3=CC=2)=C1 SMBSMAXNHQVHLG-OZXNKBQZSA-N 0.000 claims 1
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 claims 1
- FZEQPRGPLDVEOE-UHFFFAOYSA-N 2-phenoxyhexanoic acid Chemical compound CCCCC(C(O)=O)OC1=CC=CC=C1 FZEQPRGPLDVEOE-UHFFFAOYSA-N 0.000 claims 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 claims 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 claims 1
- WWZKQHOCKIZLMA-UHFFFAOYSA-N Caprylic acid Natural products CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 claims 1
- 201000003883 Cystic fibrosis Diseases 0.000 claims 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 claims 1
- 206010016654 Fibrosis Diseases 0.000 claims 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 claims 1
- 241000097929 Porphyria Species 0.000 claims 1
- 208000010642 Porphyrias Diseases 0.000 claims 1
- 239000002262 Schiff base Substances 0.000 claims 1
- 150000004753 Schiff bases Chemical class 0.000 claims 1
- 208000007156 Spondylarthritis Diseases 0.000 claims 1
- 208000006045 Spondylarthropathies Diseases 0.000 claims 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 claims 1
- 206010047163 Vasospasm Diseases 0.000 claims 1
- 235000011054 acetic acid Nutrition 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 claims 1
- 239000002671 adjuvant Substances 0.000 claims 1
- 150000001340 alkali metals Chemical class 0.000 claims 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 claims 1
- 229910021529 ammonia Inorganic materials 0.000 claims 1
- GONOPSZTUGRENK-UHFFFAOYSA-N benzyl(trichloro)silane Chemical compound Cl[Si](Cl)(Cl)CC1=CC=CC=C1 GONOPSZTUGRENK-UHFFFAOYSA-N 0.000 claims 1
- 150000003939 benzylamines Chemical class 0.000 claims 1
- 125000001246 bromo group Chemical group Br* 0.000 claims 1
- 159000000007 calcium salts Chemical class 0.000 claims 1
- 239000003054 catalyst Substances 0.000 claims 1
- 230000001684 chronic effect Effects 0.000 claims 1
- 235000015165 citric acid Nutrition 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 150000002148 esters Chemical class 0.000 claims 1
- 230000004761 fibrosis Effects 0.000 claims 1
- 235000019253 formic acid Nutrition 0.000 claims 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 claims 1
- 229940071870 hydroiodic acid Drugs 0.000 claims 1
- 238000001727 in vivo Methods 0.000 claims 1
- 229910003002 lithium salt Inorganic materials 0.000 claims 1
- 159000000002 lithium salts Chemical class 0.000 claims 1
- 159000000003 magnesium salts Chemical class 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 210000001595 mastoid Anatomy 0.000 claims 1
- 229940098779 methanesulfonic acid Drugs 0.000 claims 1
- HRDXJKGNWSUIBT-UHFFFAOYSA-N methoxybenzene Chemical group [CH2]OC1=CC=CC=C1 HRDXJKGNWSUIBT-UHFFFAOYSA-N 0.000 claims 1
- FUZZWVXGSFPDMH-UHFFFAOYSA-N n-hexanoic acid Natural products CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 claims 1
- 229910017604 nitric acid Inorganic materials 0.000 claims 1
- 231100000252 nontoxic Toxicity 0.000 claims 1
- 230000003000 nontoxic effect Effects 0.000 claims 1
- 239000000825 pharmaceutical preparation Substances 0.000 claims 1
- 159000000001 potassium salts Chemical class 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 235000019260 propionic acid Nutrition 0.000 claims 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 claims 1
- UDWXLZLRRVQONG-UHFFFAOYSA-M sodium hexanoate Chemical compound [Na+].CCCCCC([O-])=O UDWXLZLRRVQONG-UHFFFAOYSA-M 0.000 claims 1
- 201000005671 spondyloarthropathy Diseases 0.000 claims 1
- 239000011975 tartaric acid Substances 0.000 claims 1
- 235000002906 tartaric acid Nutrition 0.000 claims 1
- 125000004299 tetrazol-5-yl group Chemical group [H]N1N=NC(*)=N1 0.000 claims 1
- 125000003545 alkoxy group Chemical group 0.000 abstract 1
- 244000144972 livestock Species 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/12—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/18—Halogen atoms or nitro radicals
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pain & Pain Management (AREA)
- Neurosurgery (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Immunology (AREA)
- Pulmonology (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Quinoline Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB9414590A GB9414590D0 (en) | 1994-07-20 | 1994-07-20 | Chemical compounds |
| GB9414590.1 | 1994-07-20 | ||
| PCT/DK1995/000223 WO1996002506A1 (en) | 1994-07-20 | 1995-06-07 | Quinoline derivatives as leukotriene antagonists |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR970704691A true KR970704691A (ko) | 1997-09-06 |
Family
ID=10758585
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1019970700296A Withdrawn KR970704691A (ko) | 1994-07-20 | 1995-06-07 | 류코트리엔 길항제로서의 퀴놀린 유도체(Quinoline derivatives as leukotriene antagonists) |
Country Status (13)
| Country | Link |
|---|---|
| EP (1) | EP0773931A1 (cs) |
| JP (1) | JPH10504026A (cs) |
| KR (1) | KR970704691A (cs) |
| CN (1) | CN1152915A (cs) |
| AU (1) | AU686820B2 (cs) |
| CA (1) | CA2192478A1 (cs) |
| CZ (1) | CZ284799B6 (cs) |
| FI (1) | FI970143A7 (cs) |
| GB (1) | GB9414590D0 (cs) |
| HU (2) | HUT76443A (cs) |
| NZ (1) | NZ287850A (cs) |
| PL (1) | PL318106A1 (cs) |
| WO (1) | WO1996002506A1 (cs) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2761687B1 (fr) * | 1997-04-08 | 2000-09-15 | Centre Nat Rech Scient | Derives de quinoleines, possedant notamment des proprietes antivirales, leurs preparations et leurs applications biologiques |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8728051D0 (en) * | 1987-12-01 | 1988-01-06 | Leo Pharm Prod Ltd | Chemical compounds |
| US4918081A (en) * | 1988-06-20 | 1990-04-17 | Rorer Pharmaceutical Corp. | Quinoline derivatives and use thereof as antagonists of leukotriene d4 |
| GB9216768D0 (en) * | 1992-08-07 | 1992-09-23 | Leo Pharm Prod Ltd | Chemical compounds |
-
1994
- 1994-07-20 GB GB9414590A patent/GB9414590D0/en active Pending
-
1995
- 1995-06-07 WO PCT/DK1995/000223 patent/WO1996002506A1/en not_active Ceased
- 1995-06-07 KR KR1019970700296A patent/KR970704691A/ko not_active Withdrawn
- 1995-06-07 HU HU9603342A patent/HUT76443A/hu unknown
- 1995-06-07 PL PL95318106A patent/PL318106A1/xx unknown
- 1995-06-07 AU AU26696/95A patent/AU686820B2/en not_active Ceased
- 1995-06-07 CZ CZ963529A patent/CZ284799B6/cs not_active IP Right Cessation
- 1995-06-07 JP JP8504596A patent/JPH10504026A/ja active Pending
- 1995-06-07 NZ NZ287850A patent/NZ287850A/en unknown
- 1995-06-07 CA CA002192478A patent/CA2192478A1/en not_active Abandoned
- 1995-06-07 CN CN95194167A patent/CN1152915A/zh active Pending
- 1995-06-07 HU HU9603342D patent/HU9603342D0/hu unknown
- 1995-06-07 EP EP95921729A patent/EP0773931A1/en not_active Withdrawn
-
1997
- 1997-01-14 FI FI970143A patent/FI970143A7/fi unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CZ284799B6 (cs) | 1999-03-17 |
| FI970143A0 (fi) | 1997-01-14 |
| AU686820B2 (en) | 1998-02-12 |
| JPH10504026A (ja) | 1998-04-14 |
| AU2669695A (en) | 1996-02-16 |
| CA2192478A1 (en) | 1996-02-01 |
| GB9414590D0 (en) | 1994-09-07 |
| CN1152915A (zh) | 1997-06-25 |
| PL318106A1 (en) | 1997-05-12 |
| WO1996002506A1 (en) | 1996-02-01 |
| HUT76443A (en) | 1997-09-29 |
| CZ352996A3 (en) | 1997-10-15 |
| HU9603342D0 (en) | 1997-01-28 |
| EP0773931A1 (en) | 1997-05-21 |
| FI970143A7 (fi) | 1997-01-14 |
| NZ287850A (en) | 1998-05-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US7329753B2 (en) | Quinoline and isoquinoline derivatives, a process for their production and their use as inflammation inhibitors | |
| US6897224B2 (en) | Quinoline and isoquinoline derivatives, a process for their production and their use as inflammation inhibitors | |
| DE69329727T2 (de) | Neue imidazol derivate, ihre herstellung und therapeutische verwendung | |
| KR870000809B1 (ko) | 1,4-디하이드로피리딘의 제조방법 | |
| US5872119A (en) | 2-Naphthamide derivatives and their therapeutic applications | |
| JP2002511088A (ja) | フェニルアルキル誘導体、これらの化合物を含む医薬組成物及びそれらの調製方法 | |
| JPH05247028A (ja) | １位が置換された新規な４−（４−イミダゾリル）ピペリジンと、その製造方法と、その臨床医学への応用 | |
| JP3068208B2 (ja) | Ｐｄｅｉｖ阻害性の２―シアノイミノイミダゾール誘導体 | |
| RU2006102127A (ru) | Производные хинолина и их применение в терапии | |
| AU8311691A (en) | 4-alkylimidazole derivatives and anti-hypertensive use thereof | |
| JPWO1999043652A1 (ja) | インドール誘導体および当該誘導体を含有する医薬品組成物 | |
| JPWO2011148956A1 (ja) | 縮合イミダゾール誘導体 | |
| HU186523B (en) | Process for producing quinoline derivatives | |
| US5026853A (en) | 4-substituted-2(or 3)aminocarbonyl-1-piperazineacetamide | |
| JP2021506810A (ja) | フッ素化４−（置換アミノ）フェニルカルバメート誘導体 | |
| JP4098523B2 (ja) | Ｃｎｓ障害に対するカルボニルアミノ誘導体の使用 | |
| JP2006117568A (ja) | チオフェン環を有する新規アミド誘導体及びその医薬としての用途 | |
| US6545008B1 (en) | Pyrimidine derivatives and processes for the preparation thereof | |
| JPS6322049A (ja) | 不可逆的ド−パミン−β−ヒドロキシラ−ゼ抑制剤 | |
| KR970704691A (ko) | 류코트리엔 길항제로서의 퀴놀린 유도체(Quinoline derivatives as leukotriene antagonists) | |
| HU205920B (en) | Process for producing 2-phenoxy-methyl/-3-/alkanoyl-, carboxy-, carbalkoxy- or carboxamido- -acetyl/-1,3-thiazolidine derivatives and pharmaceutical compositions containing them | |
| CN101023077B (zh) | 生产对映体咪唑化合物的方法 | |
| JPH0515704B2 (cs) | ||
| KR950701319A (ko) | 이소세린 유도체 및 류코트리엔 길항물질로서의 이의 용도(Isoserine derivatives and their use as leukotriene antagonists) | |
| JPS63255268A (ja) | ドーパミン−β−ヒドロキシラーゼ抑制剤 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
Patent event date: 19970117 Patent event code: PA01051R01D Comment text: International Patent Application |
|
| PG1501 | Laying open of application | ||
| PC1203 | Withdrawal of no request for examination | ||
| WITN | Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid |